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Values are mean AE SD or n/N (%).
CHADS2 ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, and stroke, transient ischemic attack, or thromboembolism; CHA2DS2-VASc ¼ congestive heart failure, hypertension, age $75 years, diabetes mellitus, and stroke, transient ischemic attack, or thromboembolism; vascular disease, age 65 to 74 years, and female sex; MI ¼ myocardial infarction; NOAF ¼ new-onset atrial fibrillation or flutter; SYNTAX ¼ Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery. By multivariable analysis, the independent predictors of NOAF in patients undergoing CABG were older age, greater BMI, and reduced LVEF ( Table 3 ). Table 4) . Patients with NOAF were more frequently discharged with anticoagulant therapy with either warfarin or a novel oral anticoagulant agent, whereas dual antiplatelet therapy was more commonly prescribed to patients without NOAF.
Aspirin was equally prescribed in both groups.
Antiarrhythmic medications and diuretics were also more frequently used in patients with NOAF.
CLINICAL OUTCOMES. The development of in-hospital NOAF was associated with increased unadjusted 30-day rates of major and minor bleeding, but not with adverse cardiovascular events; after multivariable adjustment adjusted for differences in baseline characteristics, the 30-day risk for the composite outcome of death, MI, or stroke was higher in patients with NOAF compared with patients without NOAF (Online Table 2 ). At 3 years, in addition to major and minor bleeding, NOAF was associated with increased rates of all-cause death, cardiovascular death, stroke, and the primary composite endpoint of death, MI, or stroke ( Table 5) . By multivariable analysis, NOAF was an independent predictor of all-cause death, cardiovascular death, stroke, and the primary composite outcome of all-cause death, MI, or stroke at 3 years in the overall population and in the CABG-treated group (Table 6 ). Values are n/N (%).
ACE ¼ angiotensin-converting enzyme; ADP ¼ adenosine diphosphate receptor; ARB ¼ angiotensin receptor blocker; other abbreviations as in Table 2 . Abbreviations as in Tables 1 and 2 . Tables 1 and 2. advanced age, increased BMI, and reduced LVEF were independent clinical predictors of NOAF after CABG for LMCAD, consistent with previous reports (7, 14, 15) .
However, although these associations were statistically significant, the C-statistics for the correlations between these risk factors and NOAF were modest, and many patients who may benefit from CABG have these characteristics (16) . Thus, although the increased periprocedural risk of NOAF should be recognized in patients with advanced age, increased BMI, and/or reduced LVEF, rather than avoiding CABG in these patients, effective pre-operative and perioperative measures (prophylactic beta-blockers or amiodarone) (17, 18) should be considered to prevent the post-surgical occurrence of NOAF. Consistent with previous reports (19, 20) , the strategy of surgical revascularization (on-pump vs. off-pump) in EXCEL was not a predictor of NOAF.
In patients undergoing on-pump CABG, the use of However, several limitations should be considered.
First, the present analysis was post hoc, and it should thus be considered hypothesis generating. Second, the absolute number of events (NOAF, stroke, and death) was modest, and not all confounders in their described relationships may have been identified.
Third, although we excluded patients with in-hospital AF before revascularization from the present analysis, a history of prior AF was not captured in the case report form and systematic screening for pre-operative AF was not done; as such, pre-procedure episodes of AF may have been missed.
Fourth, pre-CABG use of amiodarone was uncommon, and data on the rate of perioperative beta-blocker use were not collected. We thus cannot speak to the efficacy of these measures in preventing NOAF or influencing prognosis. Finally, data on arrhythmias during follow-up (including AF recurrence) were not systematically collected in the present study. 
CONCLUSIONS

